The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating Enhertu with or without radiotherapy compared to standard of care chemotherapy with or without radiotherapy as an adjuvant treatment in patients with HER2 expressing endometrial cancer. DESTINY-Endometrial02 is being conducted in collaboration with The GOG Foundation and the European Network of Gynecological Oncological Trial Groups with the French cooperative group as the lead ENGOT group. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
- Niowave expands global supply agreement with AstraZeneca for Actinium-225
- TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
- AstraZeneca Targets Costly C. Diff Recurrence With New Antibody Trial
- AstraZeneca’s AZD1163 Trial Adds Quiet Option Value in Rheumatoid Arthritis